Latest filing published 26 Jul 2019 for MetaVia Inc..
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 3 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -23.7%Entry US$610,500.00 · Close at T+365 US$465,960.00
- -12.1%Entry US$667,920.00 · Close at T+365 US$587,400.00
- -9.2%Entry US$3.15 · Close at T+365 US$2.86
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Pedro Lichtinger: trading record in brief
Pedro Lichtinger discloses dealings in 4 companies, chiefly Optimer Pharmaceuticals Inc, Asterias Biotherapeutics, Inc. and MetaVia Inc. In total, 23 filings cover trades dated from 15 November 2010 to 24 July 2019.
On the open market, the record shows 7 purchases worth €883k and 2 sales worth €1.7M. The totals do not cover 1 filing with an undisclosed amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 6 share grants and 2 option exercises.
The median purchase comes to €92k. After 3 purchases with a full 90-day history, the hit rate stands at 67% and the median 90-day move at +16.9%. Past outcomes like these are no guarantee of what comes next.
The latest filing, published on 26 July 2019, reports a share grant in MetaVia Inc. The last insider purchase was made public on 14 March 2017, 3,527 days ago. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Pedro Lichtinger
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 15,000 shares0Common StockSEC:0001596771-19-000084:0
- 10,559 shares@ US$9.4722.5% of flowCommon StockSEC:0001596771-17-000022:0Canonical exit: 8 Jun 2017 (T+90)
- 39,274 shares@ US$6.7156.2% of flowCommon StockSEC:0001104659-16-139279:0
- 10,000 shares@ US$10.0021.3% of flowCommon StockSEC:0001104659-16-139279:1Canonical exit: 8 Nov 2016 (T+90)
- 128,205 shares@ US$3.90Series A Common Stock, par value $0.0001 per shareSEC:0001209191-15-012278:0Canonical exit: 10 May 2015 (T+90)
- 200,000 shares@ US$2.34Series B Common Stock, par value $0.0001 per shareSEC:0001209191-14-041793:0
- 200,000 shares0Series B Common Stock, par value $0.0001 per shareSEC:0001209191-14-041788:0
- 200,000 shares0Series B Common Stock, par value $0.0001 per shareSEC:0001209191-14-040749:0
- 120,000 sharesCommon Shares, no par valueSEC:0001209191-13-031061:0Canonical exit: 2 Sept 2013 (T+90)
- 58,000 shares@ US$11.41Common stockSEC:0001142576-13-000011:0
- 90,000 shares@ US$13.51Common stockSEC:0001142576-13-000011:1
- 58,000 shares@ US$14.63Common stockSEC:0001142576-13-000011:2
- 90,000 shares@ US$14.73Common stockSEC:0001142576-13-000011:3
- 11,000 shares@ US$9.08Common stockSEC:0001142576-12-000036:0Canonical exit: 6 Feb 2013 (T+90)
- 2,185 shares@ US$9.72Common StockSEC:0001142576-12-000017:0
- 6,250 shares@ US$3.98Common Shares, no par valueSEC:0001209191-12-022856:0Canonical exit: 10 Jul 2012 (T+90)
- 173 shares@ US$9.72Common stockSEC:0001142576-11-000033:0
- 25,000 shares@ US$8.98Common StockSEC:0001142576-11-000028:0Canonical exit: 2 Nov 2011 (T+90)
- 21,000 shares@ US$11.89Common StockSEC:0001142576-11-000027:0
- 20,000 shares@ US$12.34Common stockSEC:0001142576-11-000026:0
- 2,500 shares@ US$7.71Common stockSEC:0001142576-11-000021:0
- 20,000 shares@ US$12.34Common StockSEC:0001142576-11-000016:0
- 2,220 shares@ US$7.71Common stockSEC:0001142576-10-000038:0
23 of 23 declarations
